LOGIN  |  REGISTER
Compass Therapeutics

Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024

May 08, 2024 | Last Trade: US$0.04 0.001 2.44

ANN ARBOR, MI / ACCESSWIRE / May 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York.

Larry Heaton, Chief Executive Officer of Zomedica, will be presenting as well as holding one-on-one investor meetings throughout the day on May 15th. Interested parties can register to attend here.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

Follow Zomedica

Email Alerts: http://investors.zomedica.com

LinkedIn: https://www.linkedin.com/company/zomedica

Facebook: https://m.facebook.com/zomedica

X (formerly Twitter): https://twitter.com/zomedica

Instagram: https://www.instagram.com/zomedica_inc

Investor Relations Contact:

Zomedica Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-734-369-2555

Astria Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page